M Bio Technology Inc.

We are a biotechnology venture company founded with patented techniques based on the mycoplasma lipid antigen.
Main Image
We are attempting to overcome mycoplasma infection leading to chronic or intractable disease. This is done by putting techniques based on the mycoplasma lipid antigen, which the founder has studied, to practical use for development of a vaccine and diagnostic agent. The lipid antigen is a patented substance, and has already been registered in Japan and abroad. The diagnostic agent has been placed on the Japanese market and can be internationally ordered. We have already applied for an international patent for the vaccine, and we are now in negotiations to prepare the vaccine for the Japanese, US, and European markets.

製品・技術情報

  • Vaccine for Mycoplasma Infectious Diseases

    Vaccine for Mycoplasma Infectious Diseases

    [Product description] This is the simplest vaccine containing mycoplasma-like particles. This is because it is produced by chemically synthesizing a lipid antigen that is the same as the natural product as a raw material. In terms of its concept, the mycoplasma infection vaccine is a first-class product. This vaccine is stable in quality, because it requires no culturing step. In addition, this vaccine is safe, because it contains no adjuvants. Outline: Simplest component vaccine, whose component are chemically-synthesized lipid-antigens. Ultimately Safer vaccine without Adjuvant, cell culture. Liposome induces specific antibodies. GLP liposome could be prepared. Milestone: We are seeking a co-development and marketing partner of mycoplasma vaccine in the pharmaceutical companies and biotech industries world wide. IND, preclinical~PhI/PhII, PhIII and marketing. Also we are seeking for $ 20M investment or fund for preclinical~PhI/PhII [Market share/Ranking] This mycoplasma infection vaccine has not yet been in actual use, but we expect to prepare it for market. Even in the US market alone, 50 to 200 billion yen can be expected annually. [Intellectual property] An international patent application has already been filed, and is in the request for examination stage. [Major facilities and equipment] Mycoplasma Infectious Diseases Research Center (Chibadai Inohana Innovation Plaza, Organization for Small and Medium Enterprises and Regional Innovation, Japan). Alliance with Pharmatheuticals

  • Next generation diagnostics for Mycoplasma Infectious Diseases

    Next generation diagnostics for Mycoplasma Infectious Diseases

    [Product description] The novel diagnostic method could be used to measure IgM, IgG, and IgA, separately. And it make appropriate medical treatment possible. Outline: Trust measurement of the precise amount of antibodies in sera, to discover effective, advanced-medicine to create superior outcomes for patients. The medical treatment – traditional/complementary/orthomolecular/alternative/comprehensive/holistic/integrated therapies. Milestone: We are seeking partnering opportunities in and create global network such as clinical diagnosis, research institute, hospitals for the therapy of mycoplasma infectious diseases. [Market share/Ranking] Since April 2012 this test has been conducted at our own expense as well as in research and examinations. Our tie-ups with medical institutions are increasing, and we are recognized by a growing number of research institutions. [Intellectual property] An international patent application has already been filed, and is in the request for examination stage. Patents have already been registered in Japan, the US, and Australia. [Major facilities and equipment] Mycoplasma Infectious Diseases Research Center (Chibadai Inohana Innovation Plaza, Organization for Small and Medium Enterprises and Regional Innovation, Japan).

  • Support for the development of antibody preparations and the like related to mycoplasma infection.

    Support for the development of antibody preparations and the like related to mycoplasma infection.

    [Product description] Our diagnosis and drug discovery R&D with the synthesized pathogenic microorganism lipid antigen are based on a world-first platform technology. Antibody preparations and other drugs for mycoplasma infection can be developed using techniques based on the mycoplasma lipid antigen. [Market share/Ranking] An antibody preparation for mycoplasma infection has not yet been in actual use. However, antibody preparations for mycoplasma infection appear to be important drugs for patients with a serious illness for whom conventional antimicrobial agents have had little effect. [Intellectual property] An international patent application has already been filed, and is in the request for examination stage. Patents have already been registered in Japan, the US, and Australia. [Major facilities and equipment] Mycoplasma Infectious Diseases Research Center (Chibadai Inohana Innovation Plaza, Organization for Small and Medium Enterprises and Regional Innovation, Japan).

  • Precision Preventative Medicine for Mycoplasma Infectious Diseases

    Precision Preventative Medicine for Mycoplasma Infectious Diseases

    [Product description] Distinction between an incurable disease and Mycoplasma Infectious Diseases is confusing, and difficult. It is important to identify mycoplasma infection at an early stage, and to treat a cause of the disease curatively. Since drug resistant mycoplasma has already appeared, the early diagnosis and therapy of the mycoplasma infectious diseases become more important. Regrettably, conventional diagnosis has only been available for pneumonia, although it is critical to identify MID at early stages for effective medical treatment. The cutting-edge technology has made it possible . If the cause of incurable disease comes to be know mycoplasma infection, there comes to be seen the medical treatment which can remove the original cause of it. Therefore, it is important to identify mycoplasma infection at an early stage, and to curatively treat the real cause of the disease. This advanced medicine can be applied to the differential diagnosis of side effects of drugs, including interstitial pneumonia and Stevens-Johnson syndrome. [Intellectual property] The patents of mycoplasma vaccine have been registered worldwide. The patents of mycoplasma lipid antigens have been approved by Japan, US, etc.. [Major facilities and equipment] The advanced medicine using a new diagnostic product has been proposed since April, 2012. It becomes possible to discover mycoplasma infection at an early stage, and to treat a cause of the disease curatively with this medical treatment world wide.

会社概要

法人名

M Bio Technology Inc.

ホームページ

http://mbiotech.org/

資本金

186,210,000 (JPY)

従業員数

2

設立年月

2005

本社所在地:国

Japan

本社所在地:住所

2-1-3-1103, Fukazawa, Setagaya-ku, Tokyo, 158-0081

代表者

Kazuhiro Matsuda   President

代表電話番号

080-3498-7605

代表FAX番号

03-3705-5230


自由記載

[Company strength]
Our company is a biotechnology-related venture company founded with the patent techniques of Kazuhiro Matsuda (et al.) based on the mycoplasma lipid antigen. 

Representative director Kazuhiro Matsuda is a doctor. He obtained his doctorate from Yamaguchi University Graduate School of Medicine and served as an assistant in the Department of Microbiology, Faculty of Medicine, Tokyo Medical and Dental University. He then studied at Johns Hopkins University (US) and the National Institutes of Health (US). Dr. Matsuda has engaged in collaborations with many universities and research institutions, and is positioned at the core of our technology. 

The manager of the clinical development department, Yukie Matsuda, is a dermatologist. We are a slim company with expertise in medical care, and we have a unified process from basic research to clinical applications.

[Business description]
We are attempting to overcome mycoplasma infection by establishing innovative methods for its diagnosis, prevention, and treatment. 

This is done by putting the results of studies on the mycoplasma lipid antigen to practical use. 

Mycoplasma infection can lead to pneumonia and also asthma, arthritis, nephritis, meningitis, encephalitis, vasculitis, dermatitis, and so on. It causes various symptoms, which makes it difficult to discriminate mycoplasma infection from rheumatic disease, nervous system disease, and the like. 

We are conducting drug discovery research in an attempt to develop a vaccine and antibody preparation using techniques based on the mycoplasma lipid antigen. We are also attempting to overcome diseases related to the microbial lipid antigen by introducing techniques to analyze the lipid antigen into clinical diagnosis and treatment.

We have a foundational concept of open innovation and global development, and hope for joint development, business collaboration, and financial information and support.

[Industry]
Drug discovery

[Strength of products/technologies]
Mycoplasma infection causes various symptoms. It is impossible to definitely diagnose this infection with any existing diagnostic agents. Our techniques are based on the mycoplasma lipid antigen, and can be applied to the development of a safe, highly effective vaccine. An international patent application has already been filed and is in the request for examination stage. It is easy to control the vaccine quality. This is because a lipid antigen that is the same as the natural product is chemically synthesized as a vaccine raw material and no culturing is conducted. The vaccine is safe and has stable effects, because it contains no impurities or adjuvants (artificial products augmenting immune response). For the same reasons, the diagnostic agent produced with this lipid antigen is also excellent in quality.

[Representative's message]
We are putting techniques based on the mycoplasma lipid antigen to practical use for the development of a vaccine and diagnostic agent. Founder Kazuhiro Matsuda has been studying these techniques since before the foundation of the company. Our aim is to overcome mycoplasma infection leading to chronic or intractable disease. The lipid antigen is a patented substance and has already been registered in Japan and overseas. The diagnostic agent produced with this lipid antigen for research and examination has been placed on the Japanese market. We have prepared a system for receiving international orders.  Moreover, we have developed a mycoplasma infection vaccine, for which we have filed an international patent application. We are now negotiating with authorities, companies, and investors to prepare the vaccine for the Japanese, US, and European markets.

[Company structure for market development/overseas expansion]
We will make international contracts and engage in international trade in the future, so we are consulting an external consultant familiar with international contracts.

Representative director Kazuhiro Matsuda is a doctor. He obtained his doctorate from Yamaguchi University Graduate School of Medicine and served as an assistant in the Department of Microbiology, Faculty of Medicine, Tokyo Medical and Dental University. He then studied at Johns Hopkins University (US) and the National Institutes of Health (US). Dr. Matsuda has engaged in collaborations with many universities and research institutions, and is positioned at the core of our technology. 

[Market share/Ranking]
The mycoplasma infection vaccine has not yet been in actual use. However, a new diagnostic agent for mycoplasma infection has been marketed domestically, and its sales have been increasing. We are in negotiations to expand the sales network overseas in the future.

[Awards and media coverage]
Housing grant in the second half of FY 2012 by Himawari High-Tech Venture Development Foundation (Public Interest Incorporated Foundation).

[Joint research and development]
A patent application we filed in collaboration with Chiba University has already been registered in Japan. An international patent application we filed together with the National Institute of Infectious Diseases and National Institute of Advanced Industrial Science and Technology is in the request for examination stage.

[Other sites]
Mycoplasma Infectious Diseases Research Center 

[Transaction form]
We will negotiate with each individual company about the vaccine for mycoplasma infection and newly developed drugs for diseases due to mycoplasma infection. We can receive orders for the mycoplasma lipid antigen-antibody test from clinics and research institutions in Japan and overseas.

[Main Clients / Business History (domestic)]
We have already received orders for the mycoplasma lipid antigen/antibody test from a number of clinics and university hospitals through our analysis center.

[Main Clients / Business History (overseas)]
We are now negotiating with overseas companies, universities, and so on.

[Exhibition History/Information]
Bio Japan 2013; BIO Europe Spring 2013; Bio Japan 2014 (scheduled); Biotech Showcase 2014; BIO Europe Spring 2014 (scheduled).

日本語ページ掲載情報

https://jgoodtech.jp/ja_JP/web/jc0000000000429/jpn


類似する企業はこちら

類似する企業はありませんでした。